#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=Rarely , such influenza vaccines can cause allergic reactions such as hives , rapid swelling of deeper skin layers and tissues , asthma or a severe multisystem allergic reaction due to hypersensitivity to certain vaccine components .
1-1	0-6	Rarely	_	_	_	_
1-2	7-8	,	_	_	_	_
1-3	9-13	such	substance[2]	new[2]	coref	2-2[0_2]
1-4	14-23	influenza	abstract|substance[2]	new|new[2]	coref	3-12
1-5	24-32	vaccines	substance[2]	new[2]	_	_
1-6	33-36	can	_	_	_	_
1-7	37-42	cause	_	_	_	_
1-8	43-51	allergic	event[3]	new[3]	_	_
1-9	52-61	reactions	event[3]	new[3]	_	_
1-10	62-66	such	event[3]	new[3]	_	_
1-11	67-69	as	event[3]	new[3]	_	_
1-12	70-75	hives	event[3]|abstract	new[3]|new	_	_
1-13	76-77	,	event[3]	new[3]	_	_
1-14	78-83	rapid	event[3]|event[5]	new[3]|new[5]	_	_
1-15	84-92	swelling	event[3]|event[5]	new[3]|new[5]	_	_
1-16	93-95	of	event[3]|event[5]	new[3]|new[5]	_	_
1-17	96-102	deeper	event[3]|event[5]|abstract[7]	new[3]|new[5]|new[7]	_	_
1-18	103-107	skin	event[3]|event[5]|object|abstract[7]	new[3]|new[5]|new|new[7]	_	_
1-19	108-114	layers	event[3]|event[5]|abstract[7]	new[3]|new[5]|new[7]	_	_
1-20	115-118	and	event[3]|event[5]	new[3]|new[5]	_	_
1-21	119-126	tissues	event[3]|event[5]|object	new[3]|new[5]|new	_	_
1-22	127-128	,	event[3]	new[3]	_	_
1-23	129-135	asthma	event[3]|abstract	new[3]|new	_	_
1-24	136-138	or	event[3]	new[3]	_	_
1-25	139-140	a	event[3]|abstract[11]	new[3]|new[11]	_	_
1-26	141-147	severe	event[3]|abstract[11]	new[3]|new[11]	_	_
1-27	148-159	multisystem	event[3]|abstract|abstract[11]	new[3]|new|new[11]	_	_
1-28	160-168	allergic	event[3]|abstract[11]	new[3]|new[11]	_	_
1-29	169-177	reaction	event[3]|abstract[11]	new[3]|new[11]	_	_
1-30	178-181	due	_	_	_	_
1-31	182-184	to	_	_	_	_
1-32	185-201	hypersensitivity	abstract[12]	new[12]	_	_
1-33	202-204	to	abstract[12]	new[12]	_	_
1-34	205-212	certain	abstract[12]|substance[14]	new[12]|new[14]	_	_
1-35	213-220	vaccine	abstract[12]|substance|substance[14]	new[12]|new|new[14]	coref	11-18
1-36	221-231	components	abstract[12]|substance[14]	new[12]|new[14]	_	_
1-37	232-233	.	_	_	_	_

#Text=Live vaccines are given via a nasal spray , and can commonly cause runny nose , nasal congestion , cough , and can less frequently cause sore throat , low grade fever , irritability and head- and muscle- aches .
2-1	234-238	Live	_	_	_	_
2-2	239-247	vaccines	substance	giv	coref	3-11[29_0]
2-3	248-251	are	_	_	_	_
2-4	252-257	given	_	_	_	_
2-5	258-261	via	_	_	_	_
2-6	262-263	a	object[16]	new[16]	_	_
2-7	264-269	nasal	object[16]	new[16]	_	_
2-8	270-275	spray	object[16]	new[16]	_	_
2-9	276-277	,	_	_	_	_
2-10	278-281	and	_	_	_	_
2-11	282-285	can	_	_	_	_
2-12	286-294	commonly	_	_	_	_
2-13	295-300	cause	_	_	_	_
2-14	301-306	runny	object[17]	new[17]	_	_
2-15	307-311	nose	object[17]	new[17]	_	_
2-16	312-313	,	_	_	_	_
2-17	314-319	nasal	object[18]	new[18]	_	_
2-18	320-330	congestion	object[18]	new[18]	_	_
2-19	331-332	,	_	_	_	_
2-20	333-338	cough	abstract	new	_	_
2-21	339-340	,	_	_	_	_
2-22	341-344	and	_	_	_	_
2-23	345-348	can	_	_	_	_
2-24	349-353	less	_	_	_	_
2-25	354-364	frequently	_	_	_	_
2-26	365-370	cause	_	_	_	_
2-27	371-375	sore	object[20]	new[20]	_	_
2-28	376-382	throat	object[20]	new[20]	_	_
2-29	383-384	,	_	_	_	_
2-30	385-388	low	abstract[22]	new[22]	_	_
2-31	389-394	grade	abstract|abstract[22]	new|new[22]	_	_
2-32	395-400	fever	abstract[22]	new[22]	_	_
2-33	401-402	,	_	_	_	_
2-34	403-415	irritability	abstract	new	_	_
2-35	416-419	and	_	_	_	_
2-36	420-425	head-	object	new	_	_
2-37	426-429	and	_	_	_	_
2-38	430-437	muscle-	abstract[25]	new[25]	_	_
2-39	438-443	aches	abstract[25]	new[25]	_	_
2-40	444-445	.	_	_	_	_

#Text=Wheezing and vomiting episodes have been described in children receiving live influenza vaccines .
3-1	446-454	Wheezing	_	_	_	_
3-2	455-458	and	_	_	_	_
3-3	459-467	vomiting	abstract[26]	new[26]	_	_
3-4	468-476	episodes	abstract[26]	new[26]	_	_
3-5	477-481	have	_	_	_	_
3-6	482-486	been	_	_	_	_
3-7	487-496	described	_	_	_	_
3-8	497-499	in	_	_	_	_
3-9	500-508	children	person	new	_	_
3-10	509-518	receiving	_	_	_	_
3-11	519-523	live	substance[29]	giv[29]	coref	7-13[0_29]
3-12	524-533	influenza	abstract|substance[29]	giv|giv[29]	_	_
3-13	534-542	vaccines	substance[29]	giv[29]	_	_
3-14	543-544	.	_	_	_	_

#Text=( (
4-1	545-546	(	_	_	_	_
4-2	547-548	(	_	_	_	_

#Text=MM
5-1	549-551	MM	person	new	coref	19-1

#Text=) )
6-1	552-553	)	_	_	_	_
6-2	554-555	)	_	_	_	_

#Text=What action has the WHO taken , if any , to insure vaccines are available ?
7-1	556-560	What	abstract[31]	new[31]	_	_
7-2	561-567	action	abstract[31]	new[31]	_	_
7-3	568-571	has	_	_	_	_
7-4	572-575	the	_	_	_	_
7-5	576-579	WHO	_	_	_	_
7-6	580-585	taken	_	_	_	_
7-7	586-587	,	_	_	_	_
7-8	588-590	if	_	_	_	_
7-9	591-594	any	_	_	_	_
7-10	595-596	,	_	_	_	_
7-11	597-599	to	_	_	_	_
7-12	600-606	insure	_	_	_	_
7-13	607-615	vaccines	substance	giv	coref	12-27[52_0]
7-14	616-619	are	_	_	_	_
7-15	620-629	available	_	_	_	_
7-16	630-631	?	_	_	_	_

#Text=( (
8-1	632-633	(	_	_	_	_
8-2	634-635	(	_	_	_	_

#Text=KM
9-1	636-638	KM	quantity	new	coref	24-1

#Text=) )
10-1	639-640	)	_	_	_	_
10-2	641-642	)	_	_	_	_

#Text=During the first stages of the pandemic in 2009 , the Director-General highlighted the need to make vaccine and medicines available to countries who would be unable to access them on their own .
11-1	643-649	During	_	_	_	_
11-2	650-653	the	abstract[34]	new[34]	ana	11-30[0_34]
11-3	654-659	first	abstract[34]	new[34]	_	_
11-4	660-666	stages	abstract[34]	new[34]	_	_
11-5	667-669	of	abstract[34]	new[34]	_	_
11-6	670-673	the	abstract[34]|event[35]	new[34]|new[35]	coref	12-4[0_35]
11-7	674-682	pandemic	abstract[34]|event[35]	new[34]|new[35]	_	_
11-8	683-685	in	abstract[34]	new[34]	_	_
11-9	686-690	2009	abstract[34]|time	new[34]|new	coref	43-3
11-10	691-692	,	_	_	_	_
11-11	693-696	the	person[37]	new[37]	_	_
11-12	697-713	Director-General	person[37]	new[37]	_	_
11-13	714-725	highlighted	_	_	_	_
11-14	726-729	the	abstract[38]	new[38]	_	_
11-15	730-734	need	abstract[38]	new[38]	_	_
11-16	735-737	to	_	_	_	_
11-17	738-742	make	_	_	_	_
11-18	743-750	vaccine	substance	giv	coref	12-5
11-19	751-754	and	_	_	_	_
11-20	755-764	medicines	substance[40]	new[40]	_	_
11-21	765-774	available	substance[40]	new[40]	_	_
11-22	775-777	to	_	_	_	_
11-23	778-787	countries	place	new	coref	12-12[48_0]
11-24	788-791	who	_	_	_	_
11-25	792-797	would	_	_	_	_
11-26	798-800	be	_	_	_	_
11-27	801-807	unable	_	_	_	_
11-28	808-810	to	_	_	_	_
11-29	811-817	access	_	_	_	_
11-30	818-822	them	abstract	giv	ana	11-32
11-31	823-825	on	_	_	_	_
11-32	826-831	their	abstract	giv	_	_
11-33	832-835	own	_	_	_	_
11-34	836-837	.	_	_	_	_

#Text=As the WHO pandemic vaccine donation programme was first established , all countries were surveyed by WHO , and 95 identified as having no access to pandemic vaccines , and therefore eligible for donations .
12-1	838-840	As	_	_	_	_
12-2	841-844	the	abstract[47]	new[47]	_	_
12-3	845-848	WHO	abstract[47]	new[47]	_	_
12-4	849-857	pandemic	event|abstract[47]	giv|new[47]	coref	12-27
12-5	858-865	vaccine	substance|abstract[47]	giv|new[47]	coref	13-6[55_0]
12-6	866-874	donation	abstract|abstract[47]	new|new[47]	_	_
12-7	875-884	programme	abstract[47]	new[47]	_	_
12-8	885-888	was	_	_	_	_
12-9	889-894	first	_	_	_	_
12-10	895-906	established	_	_	_	_
12-11	907-908	,	_	_	_	_
12-12	909-912	all	place[48]	giv[48]	coref	13-29[62_48]
12-13	913-922	countries	place[48]	giv[48]	_	_
12-14	923-927	were	_	_	_	_
12-15	928-936	surveyed	_	_	_	_
12-16	937-939	by	_	_	_	_
12-17	940-943	WHO	_	_	_	_
12-18	944-945	,	_	_	_	_
12-19	946-949	and	_	_	_	_
12-20	950-952	95	person	new	_	_
12-21	953-963	identified	_	_	_	_
12-22	964-966	as	_	_	_	_
12-23	967-973	having	_	_	_	_
12-24	974-976	no	abstract[50]	new[50]	_	_
12-25	977-983	access	abstract[50]	new[50]	_	_
12-26	984-986	to	abstract[50]	new[50]	_	_
12-27	987-995	pandemic	abstract[50]|event|substance[52]	new[50]|giv|giv[52]	coref|coref|coref|coref	13-20[59_52]|14-12[78_0]|13-20[59_52]|14-12[78_0]
12-28	996-1004	vaccines	abstract[50]|substance[52]	new[50]|giv[52]	_	_
12-29	1005-1006	,	_	_	_	_
12-30	1007-1010	and	_	_	_	_
12-31	1011-1020	therefore	_	_	_	_
12-32	1021-1029	eligible	_	_	_	_
12-33	1030-1033	for	_	_	_	_
12-34	1034-1043	donations	object	new	_	_
12-35	1044-1045	.	_	_	_	_

#Text=Based on the pledges of donated vaccine , a plan was prepared for a two phase approach to supply sufficient vaccines for 10 % of the population in these countries ; an initial supply to cover health workers and other essential workers , equivalent to 2 % of the population , and a second supply of 8 % for other priority groups .
13-1	1046-1051	Based	_	_	_	_
13-2	1052-1054	on	_	_	_	_
13-3	1055-1058	the	abstract[54]	new[54]	_	_
13-4	1059-1066	pledges	abstract[54]	new[54]	_	_
13-5	1067-1069	of	abstract[54]	new[54]	_	_
13-6	1070-1077	donated	abstract[54]|substance[55]	new[54]|giv[55]	coref	15-8[84_55]
13-7	1078-1085	vaccine	abstract[54]|substance[55]	new[54]|giv[55]	_	_
13-8	1086-1087	,	_	_	_	_
13-9	1088-1089	a	abstract[56]	new[56]	_	_
13-10	1090-1094	plan	abstract[56]	new[56]	_	_
13-11	1095-1098	was	_	_	_	_
13-12	1099-1107	prepared	_	_	_	_
13-13	1108-1111	for	_	_	_	_
13-14	1112-1113	a	event[58]	new[58]	_	_
13-15	1114-1117	two	event[58]	new[58]	_	_
13-16	1118-1123	phase	abstract|event[58]	new|new[58]	_	_
13-17	1124-1132	approach	event[58]	new[58]	_	_
13-18	1133-1135	to	_	_	_	_
13-19	1136-1142	supply	_	_	_	_
13-20	1143-1153	sufficient	substance[59]	giv[59]	coref	14-19[0_59]
13-21	1154-1162	vaccines	substance[59]	giv[59]	_	_
13-22	1163-1166	for	substance[59]	giv[59]	_	_
13-23	1167-1169	10	substance[59]|abstract[60]	giv[59]|new[60]	appos	13-32[63_60]
13-24	1170-1171	%	substance[59]|abstract[60]	giv[59]|new[60]	_	_
13-25	1172-1174	of	substance[59]|abstract[60]	giv[59]|new[60]	_	_
13-26	1175-1178	the	substance[59]|abstract[60]|abstract[61]	giv[59]|new[60]|new[61]	_	_
13-27	1179-1189	population	substance[59]|abstract[60]|abstract[61]	giv[59]|new[60]|new[61]	_	_
13-28	1190-1192	in	substance[59]|abstract[60]|abstract[61]	giv[59]|new[60]|new[61]	_	_
13-29	1193-1198	these	substance[59]|abstract[60]|abstract[61]|place[62]	giv[59]|new[60]|new[61]|giv[62]	coref	15-4[82_62]
13-30	1199-1208	countries	substance[59]|abstract[60]|abstract[61]|place[62]	giv[59]|new[60]|new[61]|giv[62]	_	_
13-31	1209-1210	;	_	_	_	_
13-32	1211-1213	an	abstract[63]	giv[63]	_	_
13-33	1214-1221	initial	abstract[63]	giv[63]	_	_
13-34	1222-1228	supply	abstract[63]	giv[63]	_	_
13-35	1229-1231	to	_	_	_	_
13-36	1232-1237	cover	_	_	_	_
13-37	1238-1244	health	abstract|person[65]	new|new[65]	_	_
13-38	1245-1252	workers	person[65]	new[65]	_	_
13-39	1253-1256	and	_	_	_	_
13-40	1257-1262	other	person[66]	new[66]	_	_
13-41	1263-1272	essential	person[66]	new[66]	_	_
13-42	1273-1280	workers	person[66]	new[66]	_	_
13-43	1281-1282	,	person[66]	new[66]	_	_
13-44	1283-1293	equivalent	person[66]	new[66]	_	_
13-45	1294-1296	to	_	_	_	_
13-46	1297-1298	2	quantity[67]	new[67]	_	_
13-47	1299-1300	%	quantity[67]	new[67]	_	_
13-48	1301-1303	of	quantity[67]	new[67]	_	_
13-49	1304-1307	the	quantity[67]|person[68]	new[67]|new[68]	_	_
13-50	1308-1318	population	quantity[67]|person[68]	new[67]|new[68]	_	_
13-51	1319-1320	,	_	_	_	_
13-52	1321-1324	and	_	_	_	_
13-53	1325-1326	a	abstract[69]	new[69]	coref	14-4[0_69]
13-54	1327-1333	second	abstract[69]	new[69]	_	_
13-55	1334-1340	supply	abstract[69]	new[69]	_	_
13-56	1341-1343	of	abstract[69]	new[69]	_	_
13-57	1344-1345	8	abstract[69]|quantity[70]	new[69]|new[70]	_	_
13-58	1346-1347	%	abstract[69]|quantity[70]	new[69]|new[70]	_	_
13-59	1348-1351	for	abstract[69]|quantity[70]	new[69]|new[70]	_	_
13-60	1352-1357	other	abstract[69]|quantity[70]|person[72]	new[69]|new[70]|new[72]	_	_
13-61	1358-1366	priority	abstract[69]|quantity[70]|abstract|person[72]	new[69]|new[70]|new|new[72]	_	_
13-62	1367-1373	groups	abstract[69]|quantity[70]|person[72]	new[69]|new[70]|new[72]	_	_
13-63	1374-1375	.	_	_	_	_

#Text=The sequencing of supply was based on assessments of vulnerability to the pandemic , and readiness to utilize vaccines .
14-1	1376-1379	The	abstract[73]	new[73]	_	_
14-2	1380-1390	sequencing	abstract[73]	new[73]	_	_
14-3	1391-1393	of	abstract[73]	new[73]	_	_
14-4	1394-1400	supply	abstract[73]|abstract	new[73]|giv	_	_
14-5	1401-1404	was	_	_	_	_
14-6	1405-1410	based	_	_	_	_
14-7	1411-1413	on	_	_	_	_
14-8	1414-1425	assessments	abstract[75]|abstract[76]	new[75]|new[76]	ana|ana	16-9[0_76]|16-9[0_76]
14-9	1426-1428	of	abstract[75]|abstract[76]	new[75]|new[76]	_	_
14-10	1429-1442	vulnerability	abstract[75]|abstract[76]|abstract[77]	new[75]|new[76]|new[77]	_	_
14-11	1443-1445	to	abstract[75]|abstract[76]|abstract[77]	new[75]|new[76]|new[77]	_	_
14-12	1446-1449	the	abstract[75]|abstract[76]|abstract[77]|abstract[78]	new[75]|new[76]|new[77]|giv[78]	_	_
14-13	1450-1458	pandemic	abstract[75]|abstract[76]|abstract[77]|abstract[78]	new[75]|new[76]|new[77]|giv[78]	_	_
14-14	1459-1460	,	abstract[76]	new[76]	_	_
14-15	1461-1464	and	abstract[76]	new[76]	_	_
14-16	1465-1474	readiness	abstract[76]|abstract	new[76]|new	_	_
14-17	1475-1477	to	_	_	_	_
14-18	1478-1485	utilize	_	_	_	_
14-19	1486-1494	vaccines	substance	giv	coref	27-21[142_0]
14-20	1495-1496	.	_	_	_	_

#Text=To date , 25 countries have received donated H1N1 vaccine totaling more than 10 million doses , along with ancillary supplies .
15-1	1497-1499	To	_	_	_	_
15-2	1500-1504	date	time	new	_	_
15-3	1505-1506	,	_	_	_	_
15-4	1507-1509	25	place[82]	giv[82]	coref	16-4[88_82]
15-5	1510-1519	countries	place[82]	giv[82]	_	_
15-6	1520-1524	have	_	_	_	_
15-7	1525-1533	received	_	_	_	_
15-8	1534-1541	donated	substance[84]	giv[84]	coref	16-10[0_84]
15-9	1542-1546	H1N1	abstract|substance[84]	new|giv[84]	coref	21-8
15-10	1547-1554	vaccine	substance[84]	giv[84]	_	_
15-11	1555-1563	totaling	_	_	_	_
15-12	1564-1568	more	quantity[85]	new[85]	_	_
15-13	1569-1573	than	quantity[85]	new[85]	_	_
15-14	1574-1576	10	quantity[85]	new[85]	_	_
15-15	1577-1584	million	quantity[85]	new[85]	_	_
15-16	1585-1590	doses	quantity[85]	new[85]	_	_
15-17	1591-1592	,	_	_	_	_
15-18	1593-1598	along	_	_	_	_
15-19	1599-1603	with	_	_	_	_
15-20	1604-1613	ancillary	object[86]	new[86]	_	_
15-21	1614-1622	supplies	object[86]	new[86]	_	_
15-22	1623-1624	.	_	_	_	_

#Text=Another 15 to 20 countries will be receiving their vaccine shipments in the upcoming few weeks .
16-1	1625-1632	Another	place[87]	new[87]	_	_
16-2	1633-1635	15	place[87]	new[87]	_	_
16-3	1636-1638	to	place[87]	new[87]	_	_
16-4	1639-1641	20	place[87]|place[88]	new[87]|giv[88]	coref	17-1[93_88]
16-5	1642-1651	countries	place[87]|place[88]	new[87]|giv[88]	_	_
16-6	1652-1656	will	_	_	_	_
16-7	1657-1659	be	_	_	_	_
16-8	1660-1669	receiving	_	_	_	_
16-9	1670-1675	their	abstract|object[91]	giv|new[91]	coref|coref	17-7[0_91]|17-7[0_91]
16-10	1676-1683	vaccine	substance|object[91]	giv|new[91]	coref	26-13
16-11	1684-1693	shipments	object[91]	new[91]	_	_
16-12	1694-1696	in	_	_	_	_
16-13	1697-1700	the	time[92]	new[92]	_	_
16-14	1701-1709	upcoming	time[92]	new[92]	_	_
16-15	1710-1713	few	time[92]	new[92]	_	_
16-16	1714-1719	weeks	time[92]	new[92]	_	_
16-17	1720-1721	.	_	_	_	_

#Text=The 25 countries who have received shipments are : Azerbaijan , Afghanistan , Cambodia , Fiji , Kiribati , Kosovo , Laos PDR , Maldives , Mongolia , Nauru , Nicaragua , Papua New Guinea , Solomon Islands , Togo , Tonga , Vanuatu , Cuba , Honduras , El Salvador , Kenya , Samoa , Tokelau , Cook Islands , Pakistan , [ and ] Philippines
17-1	1722-1725	The	place[93]	giv[93]	coref	17-10[95_93]
17-2	1726-1728	25	place[93]	giv[93]	_	_
17-3	1729-1738	countries	place[93]	giv[93]	_	_
17-4	1739-1742	who	_	_	_	_
17-5	1743-1747	have	_	_	_	_
17-6	1748-1756	received	_	_	_	_
17-7	1757-1766	shipments	object	giv	_	_
17-8	1767-1770	are	_	_	_	_
17-9	1771-1772	:	_	_	_	_
17-10	1773-1783	Azerbaijan	place[95]	giv[95]	_	_
17-11	1784-1785	,	place[95]	giv[95]	_	_
17-12	1786-1797	Afghanistan	place[95]|place	giv[95]|new	_	_
17-13	1798-1799	,	place[95]	giv[95]	_	_
17-14	1800-1808	Cambodia	place[95]|place	giv[95]|new	_	_
17-15	1809-1810	,	place[95]	giv[95]	_	_
17-16	1811-1815	Fiji	place[95]|place	giv[95]|new	_	_
17-17	1816-1817	,	place[95]	giv[95]	_	_
17-18	1818-1826	Kiribati	place[95]|place	giv[95]|new	_	_
17-19	1827-1828	,	place[95]	giv[95]	_	_
17-20	1829-1835	Kosovo	place[95]|place	giv[95]|new	_	_
17-21	1836-1837	,	place[95]	giv[95]	_	_
17-22	1838-1842	Laos	place[95]|place|place[102]	giv[95]|new|new[102]	_	_
17-23	1843-1846	PDR	place[95]|place[102]	giv[95]|new[102]	_	_
17-24	1847-1848	,	place[95]	giv[95]	_	_
17-25	1849-1857	Maldives	place[95]|place	giv[95]|new	_	_
17-26	1858-1859	,	place[95]	giv[95]	_	_
17-27	1860-1868	Mongolia	place[95]|place	giv[95]|new	_	_
17-28	1869-1870	,	place[95]	giv[95]	_	_
17-29	1871-1876	Nauru	place[95]|place	giv[95]|new	_	_
17-30	1877-1878	,	place[95]	giv[95]	_	_
17-31	1879-1888	Nicaragua	place[95]|place	giv[95]|new	_	_
17-32	1889-1890	,	place[95]	giv[95]	_	_
17-33	1891-1896	Papua	place[95]|place[107]	giv[95]|new[107]	_	_
17-34	1897-1900	New	place[95]|place[107]	giv[95]|new[107]	_	_
17-35	1901-1907	Guinea	place[95]|place[107]	giv[95]|new[107]	_	_
17-36	1908-1909	,	place[95]	giv[95]	_	_
17-37	1910-1917	Solomon	place[95]|place[108]	giv[95]|new[108]	coref	17-59[118_108]
17-38	1918-1925	Islands	place[95]|place[108]	giv[95]|new[108]	_	_
17-39	1926-1927	,	place[95]	giv[95]	_	_
17-40	1928-1932	Togo	place[95]|place	giv[95]|new	_	_
17-41	1933-1934	,	place[95]	giv[95]	_	_
17-42	1935-1940	Tonga	place[95]|place	giv[95]|new	_	_
17-43	1941-1942	,	place[95]	giv[95]	_	_
17-44	1943-1950	Vanuatu	place[95]|place	giv[95]|new	_	_
17-45	1951-1952	,	place[95]	giv[95]	_	_
17-46	1953-1957	Cuba	place[95]|place	giv[95]|new	_	_
17-47	1958-1959	,	place[95]	giv[95]	_	_
17-48	1960-1968	Honduras	place[95]|place	giv[95]|new	_	_
17-49	1969-1970	,	place[95]	giv[95]	_	_
17-50	1971-1973	El	place[95]|place[114]	giv[95]|new[114]	_	_
17-51	1974-1982	Salvador	place[95]|place[114]	giv[95]|new[114]	_	_
17-52	1983-1984	,	place[95]	giv[95]	_	_
17-53	1985-1990	Kenya	place[95]|place	giv[95]|new	_	_
17-54	1991-1992	,	place[95]	giv[95]	_	_
17-55	1993-1998	Samoa	place[95]|place	giv[95]|new	_	_
17-56	1999-2000	,	place[95]	giv[95]	_	_
17-57	2001-2008	Tokelau	place[95]|place	giv[95]|new	_	_
17-58	2009-2010	,	place[95]	giv[95]	_	_
17-59	2011-2015	Cook	place[95]|place[118]	giv[95]|giv[118]	_	_
17-60	2016-2023	Islands	place[95]|place[118]	giv[95]|giv[118]	_	_
17-61	2024-2025	,	place[95]	giv[95]	_	_
17-62	2026-2034	Pakistan	place[95]|place	giv[95]|new	_	_
17-63	2035-2036	,	place[95]	giv[95]	_	_
17-64	2037-2038	[	place[95]	giv[95]	_	_
17-65	2039-2042	and	place[95]	giv[95]	_	_
17-66	2043-2044	]	place[95]	giv[95]	_	_
17-67	2045-2056	Philippines	place[95]|place	giv[95]|new	_	_

#Text=( (
18-1	2057-2058	(	_	_	_	_
18-2	2059-2060	(	_	_	_	_

#Text=MM
19-1	2061-2063	MM	person	giv	coref	31-1

#Text=) )
20-1	2064-2065	)	_	_	_	_
20-2	2066-2067	)	_	_	_	_

#Text=Last November , the WHO stated the H1N1 virus is world 's most dominant virus .
21-1	2068-2072	Last	time[122]	new[122]	_	_
21-2	2073-2081	November	time[122]	new[122]	_	_
21-3	2082-2083	,	_	_	_	_
21-4	2084-2087	the	_	_	_	_
21-5	2088-2091	WHO	_	_	_	_
21-6	2092-2098	stated	_	_	_	_
21-7	2099-2102	the	abstract[124]	new[124]	coref	21-11[126_124]
21-8	2103-2107	H1N1	object|abstract[124]	giv|new[124]	coref	28-32
21-9	2108-2113	virus	abstract[124]	new[124]	_	_
21-10	2114-2116	is	_	_	_	_
21-11	2117-2122	world	place[125]|abstract[126]	new[125]|giv[126]	ana|coref|ana|coref	22-2[0_126]|28-27[148_125]|22-2[0_126]|28-27[148_125]
21-12	2123-2125	's	place[125]|abstract[126]	new[125]|giv[126]	_	_
21-13	2126-2130	most	abstract[126]	giv[126]	_	_
21-14	2131-2139	dominant	abstract[126]	giv[126]	_	_
21-15	2140-2145	virus	abstract[126]	giv[126]	_	_
21-16	2146-2147	.	_	_	_	_

#Text=Is this still true ?
22-1	2148-2150	Is	_	_	_	_
22-2	2151-2155	this	abstract	giv	coref	28-32[151_0]
22-3	2156-2161	still	_	_	_	_
22-4	2162-2166	true	_	_	_	_
22-5	2167-2168	?	_	_	_	_

#Text=( (
23-1	2169-2170	(	_	_	_	_
23-2	2171-2172	(	_	_	_	_

#Text=KM
24-1	2173-2175	KM	quantity	giv	coref	35-1

#Text=) )
25-1	2176-2177	)	_	_	_	_
25-2	2178-2179	)	_	_	_	_

#Text=On February 18th , WHO concluded a four-day meeting to look at vaccine strains for seasonal influenza vaccine for the 2010 and 2011 season .
26-1	2180-2182	On	_	_	_	_
26-2	2183-2191	February	time	new	coref	28-11
26-3	2192-2196	18th	_	_	_	_
26-4	2197-2198	,	_	_	_	_
26-5	2199-2202	WHO	_	_	_	_
26-6	2203-2212	concluded	_	_	_	_
26-7	2213-2214	a	event[130]	new[130]	ana	27-1[0_130]
26-8	2215-2223	four-day	event[130]	new[130]	_	_
26-9	2224-2231	meeting	event[130]	new[130]	_	_
26-10	2232-2234	to	_	_	_	_
26-11	2235-2239	look	_	_	_	_
26-12	2240-2242	at	_	_	_	_
26-13	2243-2250	vaccine	substance|abstract[132]	giv|new[132]	coref|coref|coref|coref	26-16[134_0]|27-15[139_132]|26-16[134_0]|27-15[139_132]
26-14	2251-2258	strains	abstract[132]	new[132]	_	_
26-15	2259-2262	for	abstract[132]	new[132]	_	_
26-16	2263-2271	seasonal	abstract[132]|substance[134]	new[132]|giv[134]	coref	27-15[0_134]
26-17	2272-2281	influenza	abstract[132]|abstract|substance[134]	new[132]|new|giv[134]	coref	27-27
26-18	2282-2289	vaccine	abstract[132]|substance[134]	new[132]|giv[134]	_	_
26-19	2290-2293	for	abstract[132]|substance[134]	new[132]|giv[134]	_	_
26-20	2294-2297	the	abstract[132]|substance[134]|time[135]	new[132]|giv[134]|new[135]	coref	29-29[160_135]
26-21	2298-2302	2010	abstract[132]|substance[134]|time[135]	new[132]|giv[134]|new[135]	_	_
26-22	2303-2306	and	abstract[132]|substance[134]|time[135]	new[132]|giv[134]|new[135]	_	_
26-23	2307-2311	2011	abstract[132]|substance[134]|time[135]	new[132]|giv[134]|new[135]	_	_
26-24	2312-2318	season	abstract[132]|substance[134]|time[135]	new[132]|giv[134]|new[135]	_	_
26-25	2319-2320	.	_	_	_	_

#Text=This is part of the routine work that WHO does twice yearly to determine vaccine strains to be included in upcoming northern and southern hemisphere seasonal influenza vaccines .
27-1	2321-2325	This	event	giv	_	_
27-2	2326-2328	is	_	_	_	_
27-3	2329-2333	part	_	_	_	_
27-4	2334-2336	of	_	_	_	_
27-5	2337-2340	the	abstract[137]	new[137]	ana	28-13[0_137]
27-6	2341-2348	routine	abstract[137]	new[137]	_	_
27-7	2349-2353	work	abstract[137]	new[137]	_	_
27-8	2354-2358	that	_	_	_	_
27-9	2359-2362	WHO	_	_	_	_
27-10	2363-2367	does	_	_	_	_
27-11	2368-2373	twice	_	_	_	_
27-12	2374-2380	yearly	_	_	_	_
27-13	2381-2383	to	_	_	_	_
27-14	2384-2393	determine	_	_	_	_
27-15	2394-2401	vaccine	substance|abstract[139]	giv|giv[139]	coref|coref	42-12[202_0]|42-12[202_0]
27-16	2402-2409	strains	abstract[139]	giv[139]	_	_
27-17	2410-2412	to	_	_	_	_
27-18	2413-2415	be	_	_	_	_
27-19	2416-2424	included	_	_	_	_
27-20	2425-2427	in	_	_	_	_
27-21	2428-2436	upcoming	substance[142]	giv[142]	_	_
27-22	2437-2445	northern	substance[142]	giv[142]	_	_
27-23	2446-2449	and	substance[142]	giv[142]	_	_
27-24	2450-2458	southern	substance[142]	giv[142]	_	_
27-25	2459-2469	hemisphere	abstract|substance[142]	new|giv[142]	_	_
27-26	2470-2478	seasonal	substance[142]	giv[142]	_	_
27-27	2479-2488	influenza	abstract|substance[142]	giv|giv[142]	coref	39-25[184_0]
27-28	2489-2497	vaccines	substance[142]	giv[142]	_	_
27-29	2498-2499	.	_	_	_	_

#Text=During the scientific discussions which ended on the 18th of February , it was confirmed that the overwhelming number of influenza viruses that were isolated around the world were the pandemic H1N1 virus .
28-1	2500-2506	During	_	_	_	_
28-2	2507-2510	the	event[143]	new[143]	_	_
28-3	2511-2521	scientific	event[143]	new[143]	_	_
28-4	2522-2533	discussions	event[143]	new[143]	_	_
28-5	2534-2539	which	_	_	_	_
28-6	2540-2545	ended	_	_	_	_
28-7	2546-2548	on	_	_	_	_
28-8	2549-2552	the	_	_	_	_
28-9	2553-2557	18th	_	_	_	_
28-10	2558-2560	of	_	_	_	_
28-11	2561-2569	February	time	giv	_	_
28-12	2570-2571	,	_	_	_	_
28-13	2572-2574	it	abstract	giv	_	_
28-14	2575-2578	was	_	_	_	_
28-15	2579-2588	confirmed	_	_	_	_
28-16	2589-2593	that	_	_	_	_
28-17	2594-2597	the	abstract[146]	new[146]	coref	28-30[149_146]
28-18	2598-2610	overwhelming	abstract[146]	new[146]	_	_
28-19	2611-2617	number	abstract[146]	new[146]	_	_
28-20	2618-2620	of	abstract[146]	new[146]	_	_
28-21	2621-2630	influenza	abstract[146]|object[147]	new[146]|new[147]	coref	29-18[156_147]
28-22	2631-2638	viruses	abstract[146]|object[147]	new[146]|new[147]	_	_
28-23	2639-2643	that	_	_	_	_
28-24	2644-2648	were	_	_	_	_
28-25	2649-2657	isolated	_	_	_	_
28-26	2658-2664	around	_	_	_	_
28-27	2665-2668	the	place[148]	giv[148]	_	_
28-28	2669-2674	world	place[148]	giv[148]	_	_
28-29	2675-2679	were	_	_	_	_
28-30	2680-2683	the	abstract[149]	giv[149]	coref	29-16[155_149]
28-31	2684-2692	pandemic	abstract[149]	giv[149]	_	_
28-32	2693-2697	H1N1	abstract[149]|abstract|abstract[151]	giv[149]|giv|giv[151]	coref|coref|coref|coref	29-10[154_151]|33-18[164_0]|29-10[154_151]|33-18[164_0]
28-33	2698-2703	virus	abstract[149]|abstract[151]	giv[149]|giv[151]	_	_
28-34	2704-2705	.	_	_	_	_

#Text=The experts believe that based on this information that this virus will continue to be one of the dominant viruses in wide circulation in the coming fall and winter season .
29-1	2706-2709	The	person[152]	new[152]	_	_
29-2	2710-2717	experts	person[152]	new[152]	_	_
29-3	2718-2725	believe	_	_	_	_
29-4	2726-2730	that	_	_	_	_
29-5	2731-2736	based	_	_	_	_
29-6	2737-2739	on	_	_	_	_
29-7	2740-2744	this	abstract[153]	new[153]	_	_
29-8	2745-2756	information	abstract[153]	new[153]	_	_
29-9	2757-2761	that	_	_	_	_
29-10	2762-2766	this	abstract[154]	giv[154]	coref	42-24[207_154]
29-11	2767-2772	virus	abstract[154]	giv[154]	_	_
29-12	2773-2777	will	_	_	_	_
29-13	2778-2786	continue	_	_	_	_
29-14	2787-2789	to	_	_	_	_
29-15	2790-2792	be	_	_	_	_
29-16	2793-2796	one	abstract[155]	giv[155]	coref	37-5[167_155]
29-17	2797-2799	of	abstract[155]	giv[155]	_	_
29-18	2800-2803	the	abstract[155]|object[156]	giv[155]|giv[156]	_	_
29-19	2804-2812	dominant	abstract[155]|object[156]	giv[155]|giv[156]	_	_
29-20	2813-2820	viruses	abstract[155]|object[156]	giv[155]|giv[156]	_	_
29-21	2821-2823	in	abstract[155]|object[156]	giv[155]|giv[156]	_	_
29-22	2824-2828	wide	abstract[155]|object[156]|abstract[157]	giv[155]|giv[156]|new[157]	_	_
29-23	2829-2840	circulation	abstract[155]|object[156]|abstract[157]	giv[155]|giv[156]|new[157]	_	_
29-24	2841-2843	in	abstract[155]|object[156]|abstract[157]	giv[155]|giv[156]|new[157]	_	_
29-25	2844-2847	the	abstract[155]|object[156]|abstract[157]|time[158]	giv[155]|giv[156]|new[157]|new[158]	_	_
29-26	2848-2854	coming	abstract[155]|object[156]|abstract[157]|time[158]	giv[155]|giv[156]|new[157]|new[158]	_	_
29-27	2855-2859	fall	abstract[155]|object[156]|abstract[157]|time[158]	giv[155]|giv[156]|new[157]|new[158]	_	_
29-28	2860-2863	and	abstract[155]|object[156]|abstract[157]	giv[155]|giv[156]|new[157]	_	_
29-29	2864-2870	winter	abstract[155]|object[156]|abstract[157]|abstract|time[160]	giv[155]|giv[156]|new[157]|new|giv[160]	_	_
29-30	2871-2877	season	abstract[155]|object[156]|abstract[157]|time[160]	giv[155]|giv[156]|new[157]|giv[160]	_	_
29-31	2878-2879	.	_	_	_	_

#Text=( (
30-1	2880-2881	(	_	_	_	_
30-2	2882-2883	(	_	_	_	_

#Text=MM
31-1	2884-2886	MM	person	giv	_	_

#Text=) )
32-1	2887-2888	)	_	_	_	_
32-2	2889-2890	)	_	_	_	_

#Text=Is there anything that the WHO believes to be very important for the public to know about the H1N1 ?
33-1	2891-2893	Is	_	_	_	_
33-2	2894-2899	there	_	_	_	_
33-3	2900-2908	anything	abstract	new	_	_
33-4	2909-2913	that	_	_	_	_
33-5	2914-2917	the	_	_	_	_
33-6	2918-2921	WHO	_	_	_	_
33-7	2922-2930	believes	_	_	_	_
33-8	2931-2933	to	_	_	_	_
33-9	2934-2936	be	_	_	_	_
33-10	2937-2941	very	_	_	_	_
33-11	2942-2951	important	_	_	_	_
33-12	2952-2955	for	_	_	_	_
33-13	2956-2959	the	person[163]	new[163]	_	_
33-14	2960-2966	public	person[163]	new[163]	_	_
33-15	2967-2969	to	_	_	_	_
33-16	2970-2974	know	_	_	_	_
33-17	2975-2980	about	_	_	_	_
33-18	2981-2984	the	abstract[164]	giv[164]	coref	42-13[0_164]
33-19	2985-2989	H1N1	abstract[164]	giv[164]	_	_
33-20	2990-2991	?	_	_	_	_

#Text=( (
34-1	2992-2993	(	_	_	_	_
34-2	2994-2995	(	_	_	_	_

#Text=KM
35-1	2996-2998	KM	quantity	giv	_	_

#Text=) )
36-1	2999-3000	)	_	_	_	_
36-2	3001-3002	)	_	_	_	_

#Text=The overall impact of the pandemic has been moderate and most people experienced mild symptoms or illness .
37-1	3003-3006	The	abstract[166]	new[166]	_	_
37-2	3007-3014	overall	abstract[166]	new[166]	_	_
37-3	3015-3021	impact	abstract[166]	new[166]	_	_
37-4	3022-3024	of	abstract[166]	new[166]	_	_
37-5	3025-3028	the	abstract[166]|abstract[167]	new[166]|giv[167]	coref	41-7[192_167]
37-6	3029-3037	pandemic	abstract[166]|abstract[167]	new[166]|giv[167]	_	_
37-7	3038-3041	has	_	_	_	_
37-8	3042-3046	been	_	_	_	_
37-9	3047-3055	moderate	_	_	_	_
37-10	3056-3059	and	_	_	_	_
37-11	3060-3064	most	person[168]	new[168]	coref	38-29[178_168]
37-12	3065-3071	people	person[168]	new[168]	_	_
37-13	3072-3083	experienced	_	_	_	_
37-14	3084-3088	mild	abstract[169]	new[169]	_	_
37-15	3089-3097	symptoms	abstract[169]	new[169]	_	_
37-16	3098-3100	or	_	_	_	_
37-17	3101-3108	illness	abstract	new	coref	38-16[174_0]
37-18	3109-3110	.	_	_	_	_

#Text=However , some groups are more vulnerable and have a higher risk of complications or severe illness , for example pregnant women , infants , young children and people with chronic diseases .
38-1	3111-3118	However	_	_	_	_
38-2	3119-3120	,	_	_	_	_
38-3	3121-3125	some	person[171]	new[171]	_	_
38-4	3126-3132	groups	person[171]	new[171]	_	_
38-5	3133-3136	are	_	_	_	_
38-6	3137-3141	more	_	_	_	_
38-7	3142-3152	vulnerable	_	_	_	_
38-8	3153-3156	and	_	_	_	_
38-9	3157-3161	have	_	_	_	_
38-10	3162-3163	a	abstract[172]	new[172]	_	_
38-11	3164-3170	higher	abstract[172]	new[172]	_	_
38-12	3171-3175	risk	abstract[172]	new[172]	_	_
38-13	3176-3178	of	abstract[172]	new[172]	_	_
38-14	3179-3192	complications	abstract[172]|abstract	new[172]|new	_	_
38-15	3193-3195	or	abstract[172]	new[172]	_	_
38-16	3196-3202	severe	abstract[172]|abstract[174]	new[172]|giv[174]	coref	42-32[0_174]
38-17	3203-3210	illness	abstract[172]|abstract[174]	new[172]|giv[174]	_	_
38-18	3211-3212	,	_	_	_	_
38-19	3213-3216	for	_	_	_	_
38-20	3217-3224	example	_	_	_	_
38-21	3225-3233	pregnant	person[175]	new[175]	_	_
38-22	3234-3239	women	person[175]	new[175]	_	_
38-23	3240-3241	,	_	_	_	_
38-24	3242-3249	infants	person	new	_	_
38-25	3250-3251	,	_	_	_	_
38-26	3252-3257	young	person[177]	new[177]	_	_
38-27	3258-3266	children	person[177]	new[177]	_	_
38-28	3267-3270	and	_	_	_	_
38-29	3271-3277	people	person[178]	giv[178]	coref	41-13[195_178]
38-30	3278-3282	with	person[178]	giv[178]	_	_
38-31	3283-3290	chronic	person[178]|abstract[179]	giv[178]|new[179]	_	_
38-32	3291-3299	diseases	person[178]|abstract[179]	giv[178]|new[179]	_	_
38-33	3300-3301	.	_	_	_	_

#Text=Many of the severe cases have been due to viral pneumonia , which is harder to treat than the bacterial pneumonia normally associated with seasonal influenza .
39-1	3302-3306	Many	_	_	_	_
39-2	3307-3309	of	_	_	_	_
39-3	3310-3313	the	abstract[180]	new[180]	_	_
39-4	3314-3320	severe	abstract[180]	new[180]	_	_
39-5	3321-3326	cases	abstract[180]	new[180]	_	_
39-6	3327-3331	have	_	_	_	_
39-7	3332-3336	been	_	_	_	_
39-8	3337-3340	due	_	_	_	_
39-9	3341-3343	to	_	_	_	_
39-10	3344-3349	viral	abstract[181]	new[181]	coref	39-19[183_181]
39-11	3350-3359	pneumonia	abstract[181]	new[181]	_	_
39-12	3360-3361	,	_	_	_	_
39-13	3362-3367	which	_	_	_	_
39-14	3368-3370	is	_	_	_	_
39-15	3371-3377	harder	_	_	_	_
39-16	3378-3380	to	_	_	_	_
39-17	3381-3386	treat	_	_	_	_
39-18	3387-3391	than	_	_	_	_
39-19	3392-3395	the	abstract[183]	giv[183]	_	_
39-20	3396-3405	bacterial	object|abstract[183]	new|giv[183]	_	_
39-21	3406-3415	pneumonia	abstract[183]	giv[183]	_	_
39-22	3416-3424	normally	_	_	_	_
39-23	3425-3435	associated	_	_	_	_
39-24	3436-3440	with	_	_	_	_
39-25	3441-3449	seasonal	abstract[184]	giv[184]	coref	41-9[0_184]
39-26	3450-3459	influenza	abstract[184]	giv[184]	_	_
39-27	3460-3461	.	_	_	_	_

#Text=Many of these patients have required intensive care , which has led to intensive care units being frequently overwhelmed at the peak of the outbreak .
40-1	3462-3466	Many	_	_	_	_
40-2	3467-3469	of	_	_	_	_
40-3	3470-3475	these	person[185]	new[185]	_	_
40-4	3476-3484	patients	person[185]	new[185]	_	_
40-5	3485-3489	have	_	_	_	_
40-6	3490-3498	required	_	_	_	_
40-7	3499-3508	intensive	abstract[186]	new[186]	coref	40-15[0_186]
40-8	3509-3513	care	abstract[186]	new[186]	_	_
40-9	3514-3515	,	_	_	_	_
40-10	3516-3521	which	_	_	_	_
40-11	3522-3525	has	_	_	_	_
40-12	3526-3529	led	_	_	_	_
40-13	3530-3532	to	_	_	_	_
40-14	3533-3542	intensive	place[188]	new[188]	_	_
40-15	3543-3547	care	abstract|place[188]	giv|new[188]	_	_
40-16	3548-3553	units	place[188]	new[188]	_	_
40-17	3554-3559	being	_	_	_	_
40-18	3560-3570	frequently	_	_	_	_
40-19	3571-3582	overwhelmed	_	_	_	_
40-20	3583-3585	at	_	_	_	_
40-21	3586-3589	the	event[189]	new[189]	_	_
40-22	3590-3594	peak	event[189]	new[189]	_	_
40-23	3595-3597	of	event[189]	new[189]	_	_
40-24	3598-3601	the	event[189]|abstract[190]	new[189]|new[190]	_	_
40-25	3602-3610	outbreak	event[189]|abstract[190]	new[189]|new[190]	_	_
40-26	3611-3612	.	_	_	_	_

#Text=Most of the deaths caused by the pandemic influenza disease occurred among younger people than is the case during seasonal influenza outbreaks , including among those who were previously healthy .
41-1	3613-3617	Most	event[191]	new[191]	_	_
41-2	3618-3620	of	event[191]	new[191]	_	_
41-3	3621-3624	the	event[191]	new[191]	_	_
41-4	3625-3631	deaths	event[191]	new[191]	_	_
41-5	3632-3638	caused	_	_	_	_
41-6	3639-3641	by	_	_	_	_
41-7	3642-3645	the	abstract[192]	giv[192]	coref	42-25[0_192]
41-8	3646-3654	pandemic	abstract[192]	giv[192]	_	_
41-9	3655-3664	influenza	abstract|abstract[194]	giv|new[194]	coref|coref	41-21|41-21
41-10	3665-3672	disease	abstract[194]	new[194]	_	_
41-11	3673-3681	occurred	_	_	_	_
41-12	3682-3687	among	_	_	_	_
41-13	3688-3695	younger	person[195]	giv[195]	coref	42-3[0_195]
41-14	3696-3702	people	person[195]	giv[195]	_	_
41-15	3703-3707	than	_	_	_	_
41-16	3708-3710	is	_	_	_	_
41-17	3711-3714	the	_	_	_	_
41-18	3715-3719	case	_	_	_	_
41-19	3720-3726	during	_	_	_	_
41-20	3727-3735	seasonal	event[197]	new[197]	_	_
41-21	3736-3745	influenza	abstract|event[197]	giv|new[197]	_	_
41-22	3746-3755	outbreaks	event[197]	new[197]	_	_
41-23	3756-3757	,	_	_	_	_
41-24	3758-3767	including	_	_	_	_
41-25	3768-3773	among	_	_	_	_
41-26	3774-3779	those	_	_	_	_
41-27	3780-3783	who	_	_	_	_
41-28	3784-3788	were	_	_	_	_
41-29	3789-3799	previously	_	_	_	_
41-30	3800-3807	healthy	_	_	_	_
41-31	3808-3809	.	_	_	_	_

#Text=To protect people from infection and avoid related severe outcomes , the H1N1 vaccine is an important public health tool as long as the pandemic H1N1 virus is circulating and causing illness .
42-1	3810-3812	To	_	_	_	_
42-2	3813-3820	protect	_	_	_	_
42-3	3821-3827	people	person	giv	_	_
42-4	3828-3832	from	_	_	_	_
42-5	3833-3842	infection	abstract	new	_	_
42-6	3843-3846	and	_	_	_	_
42-7	3847-3852	avoid	_	_	_	_
42-8	3853-3860	related	abstract[200]	new[200]	_	_
42-9	3861-3867	severe	abstract[200]	new[200]	_	_
42-10	3868-3876	outcomes	abstract[200]	new[200]	_	_
42-11	3877-3878	,	_	_	_	_
42-12	3879-3882	the	substance[202]	giv[202]	coref	42-16[204_202]
42-13	3883-3887	H1N1	abstract|substance[202]	giv|giv[202]	coref	42-26
42-14	3888-3895	vaccine	substance[202]	giv[202]	_	_
42-15	3896-3898	is	_	_	_	_
42-16	3899-3901	an	substance[204]	giv[204]	coref	43-27[219_204]
42-17	3902-3911	important	substance[204]	giv[204]	_	_
42-18	3912-3918	public	substance[204]	giv[204]	_	_
42-19	3919-3925	health	abstract|substance[204]	new|giv[204]	_	_
42-20	3926-3930	tool	substance[204]	giv[204]	_	_
42-21	3931-3933	as	substance[204]	giv[204]	_	_
42-22	3934-3938	long	substance[204]	giv[204]	_	_
42-23	3939-3941	as	_	_	_	_
42-24	3942-3945	the	abstract[207]	giv[207]	_	_
42-25	3946-3954	pandemic	abstract|abstract[207]	giv|giv[207]	coref	43-22[217_0]
42-26	3955-3959	H1N1	object|abstract[207]	giv|giv[207]	coref	43-25
42-27	3960-3965	virus	abstract[207]	giv[207]	_	_
42-28	3966-3968	is	_	_	_	_
42-29	3969-3980	circulating	_	_	_	_
42-30	3981-3984	and	_	_	_	_
42-31	3985-3992	causing	_	_	_	_
42-32	3993-4000	illness	abstract	giv	_	_
42-33	4001-4002	.	_	_	_	_

#Text=Since September 2009 , more than 75 Member States and territories have implemented immunization programmes , and 290 million doses of the pandemic ( H1N1 ) 2009 vaccine have been administered .
43-1	4003-4008	Since	_	_	_	_
43-2	4009-4018	September	time[209]	new[209]	_	_
43-3	4019-4023	2009	time[209]|time	new[209]|giv	_	_
43-4	4024-4025	,	_	_	_	_
43-5	4026-4030	more	_	_	_	_
43-6	4031-4035	than	_	_	_	_
43-7	4036-4038	75	place[212]	new[212]	_	_
43-8	4039-4045	Member	person|place[212]	new|new[212]	_	_
43-9	4046-4052	States	place[212]	new[212]	_	_
43-10	4053-4056	and	_	_	_	_
43-11	4057-4068	territories	place	new	_	_
43-12	4069-4073	have	_	_	_	_
43-13	4074-4085	implemented	_	_	_	_
43-14	4086-4098	immunization	quantity|abstract[215]	new|new[215]	_	_
43-15	4099-4109	programmes	abstract[215]	new[215]	_	_
43-16	4110-4111	,	_	_	_	_
43-17	4112-4115	and	_	_	_	_
43-18	4116-4119	290	quantity[216]	new[216]	_	_
43-19	4120-4127	million	quantity[216]	new[216]	_	_
43-20	4128-4133	doses	quantity[216]	new[216]	_	_
43-21	4134-4136	of	quantity[216]	new[216]	_	_
43-22	4137-4140	the	quantity[216]|abstract[217]	new[216]|giv[217]	_	_
43-23	4141-4149	pandemic	quantity[216]|abstract[217]	new[216]|giv[217]	_	_
43-24	4150-4151	(	_	_	_	_
43-25	4152-4156	H1N1	abstract	giv	_	_
43-26	4157-4158	)	_	_	_	_
43-27	4159-4163	2009	substance[219]	giv[219]	_	_
43-28	4164-4171	vaccine	substance[219]	giv[219]	_	_
43-29	4172-4176	have	_	_	_	_
43-30	4177-4181	been	_	_	_	_
43-31	4182-4194	administered	_	_	_	_
43-32	4195-4196	.	_	_	_	_
